ROS Therapeutics
Specialised and sincere counselling has ensured capital and created security for new Danish biotech company
ROS Therapeutics is a newly founded Danish biotech company seeking to revolutionise treatment for patients suffering from rheumatoid arthritis through an improved methotrexate agent called Targeted-MTX; a pharmaceutical without the unfortunate side effects often caused by methotrexate in arthritis patients. This is ensured by targeting the medicine to only work where the patient is afflicted.
Initially, the biotech company had approached a larger law firm to help raise capital but was left feeling uncertain about the counselling they received. Their next recommendation was attorney and partner in BACH Law, Ricki Boye, who quickly convinced ROS Therapeutics that a working partnership with him would make life easier for the newly founded biotech company.
“I don’t think I could have found a better attorney. Ricki shows great interest in our company and is incredibly sincere. He has advised smaller businesses like us before and has experience with raising capital. It de-dramatized the entire process for us,” says Hanne Damgaard Jensen, CEO and founder of ROS Therapeutics.
Ricki Boye has drawn up the necessary documents and helped ROS Therapeutics raise millions in capital. It means a lot to Hanne Damgaard Jensen that she has a trusted advisor who is always available.
“Ricki is easy to get in touch with, he knows our business and we always communicate directly with him. It’s a clear advantage to using one of the larger law firms, where you’re thrown around between different employees and get the impression that they’re just looking to make money. With Ricki we know that we’re spending our money on the right things,” explains Hanne Damgaard Jensen.
